Avapritinib for indolent systemic mastocytosis

2 Views

07/09/23

Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, discusses the potential of avapritinib to address the unmet needs of patients with indolent systemic mastocytosis. Dr Bose speaks on the ongoing pivotal PIONEER trial (NCT03731260) which seeks to investigate the efficacy of avapritinib for the treatment of indolent systemic mastocytosis. The primary endpoint of the study is to determine whether 30% of patients report an improvement in symptoms through a questionnaire. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.